This figure depicts a spline regression analysis adjusted for covariates. The shaded areas of the curves indicate 95% confidence intervals.2
This figure depicts a spline regression analysis adjusted for covariates. The shaded areas of the curves indicate 95% confidence intervals.2
LOKELMA® (sodium zirconium cyclosilicate) is not indicated to reduce the risk of death.3
Serum K+ ≥5.0 mEq/L was associated with an increased risk of all-cause mortality in patients with HF, diabetes, CKD, all 3, or none of these comorbidities.2
Retrospective study of 911,698 patients from multiple integrated health delivery networks (Humedica). Control group included 338,297 individuals without known HF, CKD, diabetes, cardiovascular disease, or hypertension. Patient data came from private insurers, Medicare and Medicaid users, and uninsured individuals.2
CKD=chronic kidney disease; HF=heart failure.
Despite guideline recommendations, RAAS inhibitor therapy was frequently reduced or discontinued to manage hyperkalemia1
In 1 study, almost 50% of patients who experienced a moderate-to-severe* hyperkalemia event had their RAAS inhibitor stopped or reduced1
In this analysis from the Humedica database of health records, medical data were analyzed for 66,862 patients with hyperkalemia. Patients with at least 1 outpatient RAAS inhibitor prescription were included in the 12-month analysis. Patients with end-stage renal disease, CKD stage 5, and acute kidney injury were excluded.1
*Moderate-to-severe hyperkalemia was defined as serum K+ ≥5.5 mEq/L.1
CKD=chronic kidney disease; HF=heart failure; KDIGO=Kidney Disease: Improving Global Outcomes; RAAS=renin-angiotensin-aldosterone system.
ADVERSE REACTIONS: The most common adverse reaction in non-dialysis patients with LOKELMA was mild to moderate edema. In placebo-controlled trials up to 28 days, edema was reported in 4.4%, 5.9%, 16.1% of non-dialysis patients treated with 5 g, 10 g, and 15 g of LOKELMA once daily, respectively vs 2.4% of non-dialysis patients receiving placebo.
DRUG INTERACTIONS: LOKELMA can transiently increase gastric pH. In general, oral medications with pH-dependent solubility should be administered at least 2 hours before or 2 hours after LOKELMA. Spacing is not needed if it has been determined the concomitant medication does not exhibit pH-dependent solubility.
INDICATION AND LIMITATION OF USE:
LOKELMA is indicated for the treatment of hyperkalemia in adults.
LOKELMA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action.
Please read full Prescribing Information for LOKELMA.
You may report side effects related to AstraZeneca products by clicking here.
ADVERSE REACTIONS: The most common adverse reaction in non-dialysis patients with LOKELMA was mild to moderate edema. In placebo-controlled trials up to 28 days, edema was reported in 4.4%, 5.9%, 16.1% of non-dialysis patients treated with 5 g, 10 g, and 15 g of LOKELMA once daily, respectively vs 2.4% of non-dialysis patients receiving placebo.
DRUG INTERACTIONS: LOKELMA can transiently increase gastric pH. In general, oral medications with pH-dependent solubility should be administered at least 2 hours before or 2 hours after LOKELMA. Spacing is not needed if it has been determined the concomitant medication does not exhibit pH-dependent solubility.
INDICATION AND LIMITATION OF USE
LOKELMA is indicated for the treatment of hyperkalemia in adults.
LOKELMA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action.
Please read full Prescribing Information for LOKELMA.
You may report side effects related to AstraZeneca products by clicking here.